2 Your Health: New technology could help with early diagnosis of Autism
According to the CDC, one in 36 children in the United States have autism. Despite its prevalence, many families still have to wait months before they can get their child into a specialist to be diagnosed.
But a new diagnostic tool developed by Cleveland Clinic hopes to change that.
'On average, parents suspect something is wrong with their child's development at about a year of age. However, the diagnosis is made about two to three years later on average,' said Mohammed Aldosari, MD, pediatric neurologist at Cleveland Clinic Children's. 'So, there is a huge lag, and the lag is because of the long waiting list for autism diagnostic clinics.'
Dr. Aldosari was involved with the creation and testing of Autism Eyes, which aims to help with early diagnosis.
It works by measuring a child's gaze and eye movement while they watch different videos and images. Based on the child's reactions, a diagnosis is made. Dr. Aldosari said the diagnostic tool offers many benefits, like being able to provide immediate results. It also requires little training, so primary care physicians, for example, could administer the test.
He notes that the end goal is not only to reduce wait times for diagnosis, but to get children in sooner for treatment.
'With children, there is a principle called, 'brain plasticity,' which is a very important principle in terms of responding to treatment. The earlier intervention, the better the outcome,' he explained. 'And this has been proven by multiple studies. So, when we diagnose autism about a year to two, or potentially three years earlier, there is a huge impact in terms of their outcomes.'
Autism Eyes is still in development and not yet available for clinical use.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump's Diagnosis Sparks National Focus
SCOTTSDALE, ARIZONA / / July 24, 2025 / Following reports of President Donald J. Trump's diagnosis with Chronic Venous Insufficiency (CVI), Primus Pharmaceuticals, Inc. strongly calls on healthcare providers to intensify efforts to diagnose and treat this silent epidemic affecting 25-30 million Americans because only less than <10% are actually treated. Leg swelling, heaviness, and varicose veins are often dismissed as cosmetic or "normal aging," while they can signal a dangerous progression toward severe complications including thromboembolism (blood clots), debilitating pain, non-healing leg ulcers, and compromised mobility. Widespread, Under-Recognized Health Threat CVI, also known as chronic venous disease or venous reflux disease, impacts twice (2x) as many Americans as coronary heart disease, three times (3x) peripheral arterial disease, and 30 times (30x) the number of Americans who have a heart attack each year. According to CDC, up to 900,000 Americans are affected by venous thromboembolism annually, and 60,000 to 100,000 people die each year. Millions suffer daily challenges - standing, sitting, flying - due to blood pooling in the legs, worsened by inactivity or pressure. Traditional treatments - leg elevation, compression stockings or surgical procedures - are often cumbersome, uncomfortable, underutilized, and may be expensive with added health risks. Life-Changing Solution: Vasculera® Primus offers Vasculera, the only U.S. prescription product for CVI. It is specifically formulated as a medical food for the clinical dietary management of CVI. Taken once daily, this 600mg tablet delivers highly purified, bioavailable diosmin, a flavonoid sourced from oranges, in combination with a pH buffering agent and: Calms inflammation and oxidative stress Strengthens weakened vein walls Improves overall venous function Counters localized CVI blood acidosis Manufactured in the U.S., Vasculera presents a novel naturally-derived alternative to the status quo. Expert Physician Perspectives "CVI and its manifestation in skin known as stasis dermatitis is a very common condition that can lead to significant impairment and morbidity," said Dr. Mark Nestor, MD, PhD, Board-certified Dermatologist and Voluntary Professor, Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine. "Diosmin in its bioavailable form in the pharmaceutical-grade medical food Vasculera is a natural flavonoid that has scientifically proven benefit for this condition." Board-certified Vascular Surgeon Dr. Ron Bush, MD, FACS, one of the world's foremost experts in the histology and treatment of venous disease states, "CVI is a common condition, with symptoms that may vary but are consistently linked to elevated venous pressure. In my clinical experience, Vasculera has proven to be an effective treatment option. Its active ingredient, diosmin, is well-studied and widely documented for its ability to address the inflammation associated with chronic venous hypertension. Vasculera is also well-tolerated and has no significant contraindications." Robust Clinical Backing Over 60 published peer-reviewed clinical studies confirm diosmin's effectiveness in reducing leg pain, swelling, and skin deterioration associated with CVI. Vascular medicine experts recommend Vasculera's ultra-micronized diosmin as the only U.S. product for venous ulcers and CVI symptoms, both as standalone and adjunctive therapy in national treatment guidelines. Public Health Call to Action With an aging population and more time on electronic devices fueling CVI's prevalence, Primus urges clinicians to: Proactively screen all at-risk patients for CVI Integrate proven prescription metabolic therapies like Vasculera with CVI standards of care For prescribing information, visit About Primus Pharmaceuticals Primus innovates in prescription nutritional therapies targeting metabolic causes of chronic diseases across rheumatology, dermatology, and women's health. We develop and commercialize first-in-class products and novel deliveries in Rx drugs, medical foods, and medical devices to fill key unmet needs with universal patient access not provided by traditional pharma. Visit Contact Information Randy Keating Public Relations Managerrkeating@ SOURCE: Primus Pharmaceuticals View the original press release on ACCESS Newswire Sign in to access your portfolio
CBS News
14 hours ago
- CBS News
Third human case of West Nile virus in Illinois reported in DuPage County
A Third human case of West Nile virus in Illinois has been reported, this time in DuPage County. The DuPage County Health Department confirmed the case on Thursday. The department said the individual is a Glen Ellyn resident in their 50s, and the onset of symptoms was mid-July. The Centers for Disease Control and Prevention first confirmed in June that a person downstate, specifically in Southern Illinois, was hospitalized due to complications of the virus. The second was confirmed in Lake County on July 16. The resident was said to be in their 70s and became ill earlier in the month. Symptoms of West Nile virus While most people infected with the virus do not feel sick, about one in five will develop a fever and flu-like symptoms. Other symptoms include body aches, vomiting, diarrhea, or rash. Severe illness can occur in about one in 150 people and is most likely to occur in people over age 55 or with weakened immune systems. How to prevent it West Nile virus is spread to people from infected mosquitoes, most commonly in the summer. Eight out of 10 people infected do not develop symptoms, according to the CDC. Residents are also reminded to practice the three "R's"– reduce the number of mosquitoes and remove containers outside that hold water, repel mosquitoes by using insect repellent, and report areas where water sits for more than a week. There are no medications to treat the virus. The only way to combat the virus is to prevent mosquito bites.
New York Post
15 hours ago
- New York Post
Bread may be to blame for your depression and fatigue — and cause schizophrenia
There's bad news for carboholics. A growing body of research suggests that eating bread, pasta and other grain products may trigger or worsen a wide range of psychological symptoms, including depression, anxiety and even schizophrenia. Experts warn that some people could be especially at risk, with these mealtime staples quietly sabotaging their brains every time they take a bite. 4 A protein widely found in bread, pasta and other grains could be why some people are depressed or anxious. Westend61 – Advertisement The key culprit, researchers theorize, is gluten. This naturally occurring protein — found in wheat, barley and rye — acts as a binder that gives baked goods and other foods their structure and chew. For most, it's harmless. But in others, gluten sensitivity can trigger a range of unpleasant symptoms, including bloating, diarrhea, constipation, fatigue, headaches and joint pain, according to the Cleveland Clinic. Advertisement In more serious cases, it can develop into celiac disease, an autoimmune disorder in which the body mistakes gluten for a harmful invader, like a virus. The resulting immune response triggers inflammation and damage in the small intestine — but the effects may go far beyond digestion. 'Inflammation that starts in the gut doesn't stay in the gut. [It] can have a damaging effect on the brain,' Dr. Emeran Mayer, a gastroenterologist and neuroscientist, told Psychology Today. 'When immune cells are activated, the vagus nerve system sends a signal to the brain that can trigger fatigue and depression-like behavior,' he noted. 4 Most traditional bread products contain gluten. bukhta79 – Advertisement In children, that can look like irritability or symptoms of ADHD. In adults, it may show up as brain fog, mood disorders or more serious psychiatric conditions. Take depression, for example. While around 8% of the general population is diagnosed with major depressive disorder at some point in their lives, studies suggest that people with celiac disease are hit much harder — with some research putting the rate as high as 30%. Celiac disease has also been linked to a greater risk of anxiety, panic disorder and even schizophrenia. In fact, one study found that people with celiac are three times more likely to develop schizophrenia than those without the condition. Advertisement Beyond inflammation, research suggests that damage to the gut lining caused by gluten sensitivity may also contribute to these mental health issues. That damage can interfere with the absorption of nutrients essential for brain function, including B vitamins, iron, vitamin D, magnesium and zinc. Deficiencies in any of these can lead to a variety of psychological symptoms. 4 Some studies suggest a potential link between celiac disease and an increased risk of developing schizophrenia. andriano_cz – Scientists have also found that people with schizophrenia often test positive for high levels of antibodies linked to gluten sensitivity, hinting at a possible connection between the two. These antibodies can cross the placenta, and studies show that mothers with elevated levels may increase the risk of psychosis in their children. 'We don't know everything. But it's another step closer connecting the dots about these illnesses,' Deanna L. Kelly, a psychiatry professor at the University of Maryland School of Medicine who has spent the past 15 years leading clinical trials in schizophrenia and severe mental illness, told The Telegraph. Can a gluten-free diet help? The research is mixed. Advertisement Some studies have found that a gluten-free diet can ease anxiety, depression and neurological complications in people with celiac disease or gluten sensitivity. 4 Some people with gluten sensitivity experience mood changes, including depression. SHOTPRIME STUDIO – In one trial, participants with celiac reported lower anxiety levels after following a gluten-free diet for a year. Advertisement But others show no significant improvement — and in some cases, anxiety levels remained elevated even after cutting gluten. Some experts think part of the problem may come from the psychological stress of managing a chronic health condition. 'Being on a gluten-free diet can also lead to some of these psychiatric or mental health issues, because you have to be somewhat hyper-vigilant,' Debra Silberg, a gastroenterologist and chief science officer at Beyond Celiac, told Discover Magazine. 'There's also a fear of going out and becoming exposed to gluten,' she added. Advertisement Across the country, about 1 in every 133 people — roughly 1% of the US population — is estimated to have celiac disease, according to Beyond Celiac. That adds up to around 2 million Americans. Researchers believe the number of people affected by gluten intolerance is much higher. Studies estimate that about 6% of the US population — or roughly 20 million people — may be sensitive to gluten.
